| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Karin Leder | Q37366583 |
| P2093 | author name string | Wilson ME | |
| Weller PF | |||
| P2860 | cites work | Advanced Age a Risk Factor for Illness Temporally Associated with Yellow Fever Vaccination | Q27487839 |
| Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine | Q33248480 | ||
| Longevity of rabies antibody titre in recipients of human diploid cell rabies vaccine | Q43986258 | ||
| Immunogenicity of an inactivated hepatitis A vaccine in Dutch United Nations troops | Q44022707 | ||
| A Cluster of Severe Reactions Following Improperly Administered Takeda Japanese Encephalitis Vaccine | Q44140036 | ||
| Case-control study of allergic reactions to Japanese encephalitis vaccine | Q44142665 | ||
| Simultaneous active and passive immunization against hepatitis A studied in a population of travellers | Q44600825 | ||
| Efficacy of different doses of immune serum globulin in the prevention of hepatitis A: a three-year prospective study | Q45232829 | ||
| Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later | Q45783486 | ||
| Immunization with a human diploid cell strain of rabies virus vaccine: two-year results | Q45889904 | ||
| The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults | Q47305437 | ||
| Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide vaccine in South African school children ten years after immunization | Q50127627 | ||
| The human humoral immune response to Salmonella typhi Ty21a | Q50189674 | ||
| Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults. | Q50969746 | ||
| Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy. | Q52243225 | ||
| Antibody responses to human diploid cell vaccine for rabies with and without human rabies immune globulin. | Q53436935 | ||
| Comparison of immunogenicity of two hepatitis A vaccines--VAQTA and HAVRIX--in young adults. | Q53928855 | ||
| Protection against hepatitis A by an inactivated vaccine | Q56995443 | ||
| A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children | Q57111592 | ||
| Travel-related vaccines | Q34218609 | ||
| A global review of rabies vaccines for human use | Q34432014 | ||
| Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings | Q35237369 | ||
| Immune senescence: mechanisms and clinical implications | Q35473010 | ||
| Clinical trial with inactivated hepatitis A vaccine and recommendations for its use | Q35821266 | ||
| Immunoglobulin prophylaxis for hepatitis A | Q35952811 | ||
| Evaluation of a human diploid cell strain rabies vaccine: final report of a three year study of pre-exposure immunization | Q36258204 | ||
| Acute disseminated encephalomyelitis after treatment with Japanese B encephalitis vaccine (Nakayama-Yoken and Beijing strains) | Q36881325 | ||
| Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity | Q37150030 | ||
| Modern vaccines. Rabies | Q37587682 | ||
| A cumulative review of studies on travellers, their experience of illness and the implications of these findings | Q37888593 | ||
| Combined vaccination against yellow fever and typhoid fever: a comparative trial | Q38872328 | ||
| Yellow fever vaccines | Q38894469 | ||
| Immunogenicity and acceptability of a human diploid-cell culture rabies vaccine in volunteers | Q39319027 | ||
| A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results | Q39568025 | ||
| Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0-6 schedule). | Q39591626 | ||
| A new typhoid vaccine composed of the Vi capsular polysaccharide | Q40374874 | ||
| The immunology of exceptional individuals: the lesson of centenarians. | Q40606515 | ||
| Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: antimicrobial resistance on the rise | Q40621202 | ||
| Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines | Q40629798 | ||
| A haemorrhagic fever from the Côte d'Ivoire | Q40630286 | ||
| Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine | Q40632057 | ||
| Typhoid fever in the United States, 1985-1994: changing risks of international travel and increasing antimicrobial resistance | Q40640382 | ||
| Imported yellow fever in a United States citizen | Q40644272 | ||
| Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization | Q40670167 | ||
| Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines | Q40706749 | ||
| Hepatitis A and hepatitis B: risks compared with other vaccine preventable diseases and immunization recommendations | Q40723754 | ||
| Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview | Q40752135 | ||
| Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial | Q40757649 | ||
| Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants | Q40762550 | ||
| Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee | Q40765461 | ||
| Protection against Japanese encephalitis by inactivated vaccines | Q40783257 | ||
| Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever | Q40784380 | ||
| Protective activity of Vi capsular polysaccharide vaccine against typhoid fever | Q40792174 | ||
| Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report | Q40792921 | ||
| Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation | Q40797037 | ||
| Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines | Q40806387 | ||
| Neurological complications to vaccination against Japanese encephalitis | Q40816725 | ||
| Inefficacy of the commercial live oral Ty 21a vaccine in the prevention of typhoid fever | Q40817473 | ||
| Typhoid in the United States and the Risk to the International Traveler | Q40834073 | ||
| Acute disseminated encephalomyelitis after Japanese B encephalitis vaccination | Q41854384 | ||
| Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease | Q42673894 | ||
| Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study | Q42977358 | ||
| Systemic reactions in U.S. Marine Corps personnel who received Japanese encephalitis vaccine | Q42982327 | ||
| Side-effects with Japanese encephalitis vaccine | Q42985338 | ||
| Further experience with Japanese encephalitis vaccine | Q42987105 | ||
| Yellow fever 17D vaccine virus isolated from healthy vaccinees accumulates very few mutations | Q42989633 | ||
| Anaphylaxis from yellow fever vaccine | Q42993006 | ||
| Immunisation against Japanese Encephalitis in Nepal: Experience of 1152 subjects | Q43001579 | ||
| Japanese encephalitis vaccine: persistence of antibody up to 3 years after a three-dose primary series | Q43039655 | ||
| Immunisation against Japanese encephalitis | Q43040055 | ||
| Risk factors for systemic hypersensitivity reactions after booster vaccinations with human diploid cell rabies vaccine: a nationwide prospective study | Q43213097 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1553-1566 | |
| P577 | publication date | 2001-10-04 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Travel vaccines and elderly persons: review of vaccines available in the United States | |
| P478 | volume | 33 |
| Q36740019 | Balancing the Efficacy and Safety of Vaccines in the Elderly |
| Q40061282 | Guidelines for the prevention of travel-associated illness in older adults |
| Q50114310 | Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly |
| Q80641030 | Immunogenicity and safety of a virosomal hepatitis A vaccine in HIV-positive patients |
| Q35887112 | Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study |
| Q39043124 | Immunogenicity and safety of purified vero cell rabies vaccine (PVRV) produced by Liaoning Cheng Da Co. under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese adults aged 50 and above |
| Q44638089 | Immunogenicity of combined hepatitis A and B vaccine in elderly persons |
| Q82407036 | Mucosal immunisation: Successful approaches to targeting different tissues |
| Q91901653 | Ouderen op reis |
| Q28384463 | President's address: travel medicine and principles of safe travel |
| Q35088613 | Problems and solutions to the development of vaccines in the elderly |
| Q39056372 | Real-life versus package insert: a post-marketing study on adverse-event rates of the virosomal hepatitis A vaccine Epaxal® in healthy travellers |
| Q90244901 | Retrospective analysis of older travellers attending a specialist travel health clinic |
| Q45397972 | Single dose of inactivated Japanese encephalitis vaccine with poly(gamma-glutamic acid) nanoparticles provides effective protection from Japanese encephalitis virus. |
| Q52945818 | The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. |
| Q47897366 | Translational modifications to improve vaccine efficacy in an oral influenza vaccine |
| Q39019108 | Travel-associated illness in older adults (>60 y). |
| Q37084886 | Vaccination in the elderly: an immunological perspective |
| Q38217108 | Vaccine responsiveness in the elderly: best practice for the clinic |
| Q35029094 | Viral hemorrhagic fevers including hantavirus pulmonary syndrome in the Americas |
Search more.